Printer Friendly

Positive Phase III Results for Genentech's Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine.

M2 PHARMA-August 31, 2018-Positive Phase III Results for Genentech's Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine

(C)2018 M2 COMMUNICATIONS

- Pivotal data from the Phase III HAVEN 3 study, which evaluated Hemlibra (emicizumab-kxwh) prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or older with hemophilia A without factor VIII inhibitors, were published in the 30 August, issue of the New England Journal of Medicine (NEJM), US-based biotechnology company Genentech said.

Genentech is a member of Switzerland's Roche Group (SIX: RO) (OTCQX: RHHBY).

Data from the HAVEN 3 study showed that Hemlibra prophylaxis administered subcutaneously every week or every two weeks significantly reduced treated bleeds by 96% (rate ratio [RR]=0.04; p

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 31, 2018
Words:139
Previous Article:Vertex, Genomics Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines.
Next Article:Gene Therapy Specialist ReflectionBio Receives Orphan Drug Designation from US FDA for the Treatment of Bietti's Crystalline Dystrophy.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters